Reviva Pharmaceuticals Holdings (RVPH) Accounts Payables (2018 - 2026)
Reviva Pharmaceuticals Holdings (RVPH) posted Accounts Payables of $2.1 million for Q1 2026, down 30.7% sequentially from $3.0 million in Q4 2025, and down 55.83% YoY from $4.7 million in Q1 2025.
Reviva Pharmaceuticals Holdings (RVPH) Accounts Payables (2018 - 2026) Analysis & Trends
Reviva Pharmaceuticals Holdings has reported Accounts Payables for 9 years, with the latest figure at $2.1 million in Q1 2026.
- Quarterly Accounts Payables fell 55.83% year-over-year to $2.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.1 million (down 55.83% YoY) and the FY2025 annual result came in at $3.0 million, down 52.11% from the prior year.
- Accounts Payables declined to $2.1 million in Q1 2026 per RVPH's latest filing, from $3.0 million in the prior quarter.
- Over five years, Accounts Payables peaked at $8.8 million in Q3 2024 and troughed at $1.4 million in Q1 2022.
- A 5-year average of $4.1 million and a median of $3.8 million in 2023 frame the typical range for Accounts Payables.
- The sharpest annual moves came in 2022 and 2026: Accounts Payables soared 612.68% in 2022, then tumbled 55.83% in 2026.
- Over 5 years, Accounts Payables stood at $3.5 million in 2022, then gained by 9.34% to $3.8 million in 2023, then jumped by 63.24% to $6.3 million in 2024, then plunged by 52.11% to $3.0 million in 2025, then tumbled by 30.7% to $2.1 million in 2026.
- According to Business Quant data, Accounts Payables over the past three periods registered $2.1 million, $3.0 million, and $5.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 35.57 Mn |
| 10 | Reviva Pharmaceuticals Holdings | 6.74 Mn | 6.74 Mn | - | 2.46 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.46 Mn |
| Mar 31, 2026 | 2.09 Mn |
| Dec 31, 2025 | 3.01 Mn |
| Sep 30, 2025 | 5.43 Mn |
| Jun 30, 2025 | 4.97 Mn |
| Mar 31, 2025 | 4.72 Mn |
| Dec 31, 2024 | 6.28 Mn |
| Sep 30, 2024 | 8.78 Mn |
| Jun 30, 2024 | 4.69 Mn |
| Mar 31, 2024 | 5.72 Mn |
| Dec 31, 2023 | 3.85 Mn |
| Sep 30, 2023 | 5.28 Mn |
| Jun 30, 2023 | 2.65 Mn |
| Mar 31, 2023 | 2.86 Mn |
| Dec 31, 2022 | 3.52 Mn |
| Sep 30, 2022 | 2.35 Mn |
| Jun 30, 2022 | 2.55 Mn |
| Mar 31, 2022 | 1.43 Mn |
| Sep 30, 2021 | 420,783.00 |
| Jun 30, 2021 | 358,257.00 |